Status:
COMPLETED
Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Lead Sponsor:
National Human Genome Research Institute (NHGRI)
Conditions:
Blood Coagulation Disorders
Eligibility:
All Genders
2-80 years
Brief Summary
Congenital bleeding disorders characterized by abnormal platelet granules include Gray Platelet syndrome (GPS; defective alpha-granules), Hermansky-Pudlak syndrome (HPS; defective delta-granules), and...
Detailed Description
Congenital bleeding disorders characterized by abnormal platelet granules include Gray Platelet syndrome (GPS; defective alpha-granules), Hermansky-Pudlak syndrome (HPS; defective delta-granules), and...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- This protocol will include children and adults with a clinical diagnosis of GPS, HPS, isolated delta-SPD, combined alpha delta-SPD, Griscelli disease, Chediak Higashi syndrome, Wiskott Aldrich syndrome or Thrombocytopenia absent radius syndrome. Patients whose platelets exhibit abnormal intracellular vesicle morphology will also be eligible.
- EXCLUSION CRITERIA:
- Patients younger than 2 years and older than 80 years will be excluded. Patients with severe thrombocytopenia (fewer than 20 times 10(12) platelets/L) will be excluded.
Exclusion
Key Trial Info
Start Date :
June 29 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 13 2011
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00086476
Start Date
June 29 2004
End Date
June 13 2011
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892